Clinical trial
Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)
NCT00350948 is registered in ClinicalTrials.gov with Telik as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)
- Lead sponsor
- Telik
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- May 31, 2006
- Completion date
- December 31, 2008
- Enrollment
- 244 (actual)
- Sites
- 71
Conditions
As the registry lists them; a condition with its own page is linked.